Abbott shareholders nix 'say-on-pay'; Wyeth gets Euro nod for bone med;

> Abbott shareholders voted down a proposal calling for a non-binding vote on executive compensation. The company had opposed the measure; the owners of 40% of the company's shares voted in favor. Report

> Wyeth Pharmaceuticals won European Commission approval for Conbrizatm (bazedoxifene), a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. Release

> The FDA approved a potential Johnson & Johnson blockbuster--Simponi, essentially a follow-up to Remicade--that fights three forms of arthritis caused by immune-system disorders. Report

> Several pharmacies, drugmakers and wholesalers in Ontario are facing criminal charges and $34 million in fines in an alleged scheme that saw them profit from reselling generic prescription drugs, officials said. Report

> Health products firm Omega Pharma agreed with an Indian pharmaceutical group to create a joint venture on the subcontinent that should make sales of $2.6 million in 2010. Report

> Canadian eye care company QLT reported a $1.3 million first-quarter profit, reversing a year-ago loss of $10.5 million as a 23.9 percent drop in Visudyne sales was offset by improved revenue and higher profit shares. Report

> Citing an unexpectedly high placebo response, XenoPort and GlaxoSmithKline reported this morning that their experimental therapy to treat numbness in diabetes patients failed a mid-stage trial. Report

> Novartis and Merck KGaA are leading a group of developers who are advancing a new generation of therapies for multiple sclerosis. The National Multiple Sclerosis Society says it is tracking five new pills and two infusion therapies that could be approved by 2014. Report

> Scientists are racing to gain a better understanding of the A/H1N1 strain of swine flu that has triggered an epidemic in Mexico and a public health emergency in the United States. Report

> The Johns Hopkins University School of Medicine has one of the largest public drug libraries in the world. And the stockpile of more than 3,000 drugs has proven a fertile field for researchers exploring new uses for old compounds. Article

> Scientists say they have cracked the genetic code of the new A/H1N1 flu virus that broke out in Mexico and has rapidly circumvented the globe. The new virus is the result of a genetic reassortment, where different viruses have mixed and created a new strain. Report

And Finally... GlaxoSmithKline's Tykerb may offer an option for inflammatory breast cancer when other treatments have failed, researchers said. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.